Clinical stage, commercial-stage, or any other stage science paper mills urinate in the general direction of the next dust storm with a probability of traditional commercial success equal to the life span of a bedouin before the century-old discovery of dinosaur carcass beneath camels.
Capital market actors can lament the hours chasing product revenue through the income statement, cash flow statement, and balance sheet to a fitting conclusion of whether to buy or sell a business model because the starting point, product, is a promise to pursue the creation of a product with a large amount of others people's time and money.
The puzzle of securities analysis becomes a rumination of data series with little other than a finger to lick and wind to place it in to divine direction. But in the gumbo of data there are trinkets of clues that permit the reduction of risk and increase the probability of reward for business models valued under $1 billion percolating off the radar.
We share the thoughts of our analyst, Ms Claire Voyant, as the spirit moves and the gumbo delivers
Capital market actors can lament the hours chasing product revenue through the income statement, cash flow statement, and balance sheet to a fitting conclusion of whether to buy or sell a business model because the starting point, product, is a promise to pursue the creation of a product with a large amount of others people's time and money.
The puzzle of securities analysis becomes a rumination of data series with little other than a finger to lick and wind to place it in to divine direction. But in the gumbo of data there are trinkets of clues that permit the reduction of risk and increase the probability of reward for business models valued under $1 billion percolating off the radar.
We share the thoughts of our analyst, Ms Claire Voyant, as the spirit moves and the gumbo delivers
| 19-May-20 | mcap | shorts % | rsi | sma 20 % | |
| vbiv | 2.50 | 576 | 6 | 78 | 74 |
| vxrt | 3.00 | 245 | 3 | 60 | 7 |
| zyne | 5.00 | 129 | 24 | 60 | 28 |
Comments